Innovative and versatile CEO with a progressive career history in the Life Sciences/Diagnostics industry. A visionary leader with a passion for developing new technologies to revolutionize medical practices for physicians and their patients. Extensive knowledge and expertise across clinical research, product development, and commercialization. Diplomatic with high moral standards and a driven work ethic to inspire and motivate top-performing teams. Co-author on over 95 peer-reviewed publications and inventor on more than 80 patents/ patent applications.
Martin R. Felsenthal is a Partner of HLM Venture Partners. Marty was previously a General Partner of Salix Ventures, where he focused on investments in health care services and health care information technology. Marty served on the boards of Vantage Oncology, US Renal Care, Ancillary Care Management, Vericare, AccentCare, Titan Health and Payerpath. At Salix, Marty was involved in helping management found a number of new businesses through platform acquisitions, including Vantage and Vericare. He also recruited more than 25 executives to the portfolio companies with whom he worked. He is currently a director of Aperio Technologies and Vericare Management and a board observer at Vantage Oncology. Marty also serves on the Board of the Northern California Chapter of the Crohn's and Colitis Foundation of America. He received a BA from Princeton University and an MBA from the Stanford University Graduate School of Business.
Most recently, Dr. Gottlieb served as the 23rd Commissioner of the U.S. Food and Drug Administration (FDA) from 2017 to 2019. Prior to serving as Commissioner, Dr. Gottlieb held several roles in the public and private sectors including serving as Managing Director, T.R. Winston & Company from 2013 to 2017. Dr. Gottlieb was previously the FDA’s Deputy Commissioner for Medical and Scientific Affairs from 2005 to 2007, as well as the senior advisor to the FDA Commissioner from 2003 to 2004. Dr. Gottlieb is a member of the National Academy of Medicine and is a Contributor to the financial news network, CNBC. He also serves on the boards for Pfizer, Illumina, Aetion, and Tempus.